US Broker Ratings

Arrowhead Pharmaceuticals (ARWR) Stock Analysis: Biotechnology Innovations and Market Position

Arrowhead Pharmaceuticals, Inc. (ARWR), a prominent player in the biotechnology sector, has captured investor attention with its innovative approach to tackling intractable diseases. With a robust pipeline and strategic partnerships,..

Centessa Pharmaceuticals plc (CNTA) Stock Analysis: A Biotech Gem with 56% Upside Potential

Centessa Pharmaceuticals plc (NASDAQ: CNTA) is making waves in the biotechnology sector, capturing investor attention with its promising pipeline and significant upside potential. Headquartered in Altrincham, United Kingdom, Centessa is..

Certara, Inc. (CERT) Stock Analysis: Unlocking a 41.71% Potential Upside with Innovative Biosimulation Solutions

Certara, Inc. (CERT), a leading player in the healthcare sector specializing in health information services, is making waves with its cutting-edge technology-enabled services and software products. With a current market..

Mesoblast Limited (MESO) Stock Analysis: Unpacking an 84.60% Potential Upside

Mesoblast Limited (NASDAQ: MESO) stands out in the biotechnology sector, not just for its innovative regenerative medicine products but also for the compelling investment opportunities it presents. With a market..

Schrodinger, Inc. (SDGR) Stock Analysis: Harnessing a 52.59% Upside Potential Amidst Rapid Revenue Growth

Schrödinger, Inc. (NASDAQ: SDGR), a trailblazer in the healthcare sector, is reshaping the landscape of drug discovery and materials science with its cutting-edge computational platform. With a market capitalization of..

Belite Bio, Inc (BLTE): Analyst Consensus Points to 11.52% Upside Potential in Biotech Innovator

Belite Bio, Inc (NASDAQ: BLTE) is gaining traction in the biotechnology sector with a notable market cap of $6.2 billion. Headquartered in San Diego, California, Belite Bio is a clinical-stage..

IDEAYA Biosciences (IDYA) Investor Outlook: Exploring a 42.5% Potential Upside in the Precision Oncology Space

IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is making waves in the biotechnology sector with its focus on precision medicine and oncology. As a company dedicated to the discovery and development of..

QuidelOrtho Corporation (QDEL) Stock Analysis: Navigating Potential Upside of 28.56% Amidst Market Challenges

QuidelOrtho Corporation (QDEL), a leading name in the healthcare sector specializing in medical devices, offers a compelling case for investors seeking opportunities in the diagnostic testing solutions market. With a..

Acadia Healthcare Company, Inc. (ACHC) Stock Analysis: A 46% Upside Potential Amidst Healthcare Expansion

Acadia Healthcare Company, Inc. (ACHC), a prominent player in the healthcare sector, is drawing significant investor attention with its potential upside of 46.31%. Headquartered in Franklin, Tennessee, Acadia specializes in..

Immunocore Holdings plc (IMCR) Stock Analysis: A Biotechnology Pioneer with 80% Upside Potential

Immunocore Holdings plc (NASDAQ: IMCR) is making waves in the biotechnology sector with its cutting-edge approach to immunotherapy. With a market cap of approximately $1.79 billion, this UK-based company is..

Tandem Diabetes Care, Inc. (TNDM) Stock Analysis: Assessing Future Growth in the Medical Devices Sector

Tandem Diabetes Care, Inc. (NASDAQ: TNDM) is a pivotal player in the healthcare sector, specifically within the medical devices industry. Headquartered in San Diego, California, Tandem specializes in innovative technology..

Twist Bioscience Corporation (TWST) Stock Analysis: Unveiling a 9.21% Potential Upside in Synthetic DNA Innovation

Twist Bioscience Corporation (NASDAQ: TWST), a prominent player in the healthcare sector specializing in diagnostics and research, is capturing the attention of investors with its innovative strides in synthetic DNA..

PACS Group, Inc. (PACS) Stock Analysis: A Healthcare Powerhouse with a 9% Upside Potential

PACS Group, Inc. (NASDAQ: PACS), a burgeoning name in the healthcare sector, is redefining the landscape of medical care facilities in the United States. With a market capitalization of $6.11..

Disc Medicine, Inc. (IRON) Stock Analysis: Poised for 55% Upside Potential Amid Robust Analyst Confidence

Disc Medicine, Inc. (NASDAQ: IRON), a clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to addressing serious hematologic diseases. With a market capitalization of..

ICU Medical, Inc. (ICUI) Investor Outlook: Analyzing a 22.82% Potential Upside Amidst Market Volatility

ICU Medical, Inc. (NASDAQ: ICUI) presents a compelling investment narrative within the healthcare sector, specifically in the medical instruments and supplies industry. With a market capitalization of $3.63 billion, the..

Bausch Health Companies Inc. (BHC) Stock Analysis: A Closer Look at Its Potential Upside and Financial Health

Bausch Health Companies Inc. (NYSE: BHC) stands out in the healthcare sector as a diversified specialty pharmaceutical and medical device company. Operating from Laval, Canada, Bausch Health’s market capitalization currently..

Xenon Pharmaceuticals Inc. (XENE) Stock Analysis: Exploring the 24.98% Upside Potential

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) is making waves in the biotechnology sector with a remarkable 24.98% potential upside, capturing the attention of savvy investors looking for promising opportunities in the..

LeMaitre Vascular, Inc. (LMAT) Investor Outlook: A 24.96% Upside Potential Amidst Strong Revenue Growth

LeMaitre Vascular, Inc. (NASDAQ: LMAT), a stalwart in the healthcare sector, particularly in medical instruments and supplies, offers a compelling prospect for investors seeking exposure to the vascular surgery market...

Zai Lab Limited (ZLAB): Analyst Ratings Reveal 175.93% Potential Upside for This Biotech Powerhouse

Zai Lab Limited (NASDAQ: ZLAB), a prominent player in the biotechnology sector, has captured investor attention with its robust pipeline and strategic partnerships. Based in China, Zai Lab focuses on..

HUTCHMED (China) Limited (HCM): Investor Outlook Highlights 68.54% Potential Upside

HUTCHMED (China) Limited (NASDAQ: HCM), a prominent player in the healthcare sector, offers a compelling opportunity for investors seeking exposure to the precision medicine market, particularly in oncology. With its..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds